Anticipatory judicial review can ground an Article 267 validity reference where directive transposition is imminent and the dispute is genuine

1) Introduction

In Irish Pharmaceutical Healthcare Association Ltd and Anor v The Minister for Housing, Local Government and Heritage and Ors [2026] IEHC 310, Humphreys J in the High Court (Planning & Environment) stayed domestic judicial review proceedings and made a preliminary reference to the Court of Justice of the European Union (“CJEU”) under Article 267 TFEU. The applicants—two industry representative bodies for (i) research-based pharmaceutical companies and (ii) generic/biosimilar/value-added medicines manufacturers—challenge the State’s proposed transposition (by secondary legislation under the European Communities Act 1972) of parts of Directive (EU) 2024/3019 on urban wastewater treatment (recast).

The dispute centres on the Directive’s requirement for “quaternary treatment” to remove micropollutants and, crucially, its extended producer responsibility (“EPR”) mechanism requiring producers placing human medicines and cosmetics on the market to cover at least 80% of the costs of that additional treatment.

The domestic proceedings were unusual procedurally: while Irish practice typically expects a challenge after adoption of implementing measures, the State respondents non-precedentially waived any objection to an advance challenge. That opened a clear path for an early validity reference aimed at removing uncertainty ahead of the Directive’s transposition deadline (31 July 2027).

2) Summary of the Judgment

The High Court did not decide the validity of the Directive. Instead, it:

  • identified that the applicants’ “core ground” was that the State was not entitled to transpose the Directive because the impugned provisions are allegedly invalid;
  • held that the proceedings provided a sufficient litigation context to support a validity reference, even though transposition measures had not yet been adopted;
  • formulated and referred a detailed question on whether Articles 9 and/or 10 and/or Annex III are invalid in light of Article 168 TFEU (health), Article 191(2) TFEU (polluter pays), and general principles (proportionality, equal treatment/non-discrimination, legal certainty) and/or “manifest error”;
  • requested that the CJEU treat the reference as a priority case under Article 53(3) of the CJEU Rules of Procedure;
  • adjourned (“stayed”) the substantive Irish proceedings pending the CJEU’s ruling.

A notable feature was the Court’s explanation that, because the State respondents largely declined to engage with evidence/argument on the Directive’s scientific and economic underpinnings (contending that defence is for the EU institutions), the High Court could not responsibly provide a “particularly meaningful” proposed answer to the validity question.

3) Analysis

3.1 Precedents Cited

The principal domestic authority relied on was An Taisce v. Minister for Housing, Local Government and Heritage (No. 1) [2024] IEHC 129. Humphreys J used it for two connected propositions relevant to the admissibility/utility of the reference:

  • A domestic challenge to an EU act’s validity “does not require that implementing measures have been adopted”. This matters where (as here) the impugned legal burden arises from the Directive itself (not merely from a particular Irish implementing choice).
  • A duty/necessity to refer validity questions must arise in the context of a “genuine dispute capable of being litigated”, which can include proceedings where implementing measures are anticipated. The judgment treats the combination of (i) impending transposition, (ii) the respondents’ stated approach to transposition, and (iii) concrete sectoral impacts alleged by evidence, as sufficient to constitute that genuine dispute.

The practical effect is to confirm—at least at High Court level—that Irish judicial review can serve as a vehicle for early validity scrutiny via Article 267 where a Directive is on a clear path to domestic implementation and where the dispute is not hypothetical.

3.2 Legal Reasoning

(a) What exactly was referred—and why those provisions?

The reference is targeted at the EPR architecture: Article 9 (extended producer responsibility), Article 10 (minimum requirements for producer responsibility organisations), and Annex III (defining the products caught by Article 9). The applicants’ case is not merely that Ireland might implement the Directive harshly; it is that the Directive itself mandates an 80% minimum cost-allocation to two product sectors, allegedly without an adequate evidential or rational basis.

(b) How the Court handled contested scientific/economic material at the referral stage

The applicants adduced affidavit evidence and supporting reports alleging “fundamental flaws” in the Commission’s Impact Assessment and the EPR “Feasibility Report” (including alleged data selectivity, bias, and overestimation of the pharmaceutical “toxic-weighted load”). The State respondents pleaded that the Impact Assessment was robust but did not put forward countervailing scientific evidence, instead emphasising that the EU institutions should defend validity in Luxembourg.

Humphreys J adopted a careful, procedurally conservative approach: the Court could take account of the affidavit evidence to demonstrate that an arguable (or “well-founded”) validity challenge exists, while making no findings on disputed facts. This is important because validity challenges frequently turn on whether the EU legislature committed a “manifest error” in complex assessments. At referral stage, the Irish court’s role is to ensure the question is real and material—not to pre-empt the CJEU’s merits assessment.

(c) The “agreed interpretation points” narrowed the dispute

The parties agreed two interpretive points that shaped the question:

  • Articles 9/10 do not require Member States to distinguish as such between producers of medicines and cosmetics (as opposed to product composition).
  • Article 9(3)(c) does not require Member States to determine the quantity of each relevant substance in national urban wastewater.

These concessions sharpen the applicants’ complaint: the Directive allegedly imposes a sector-level funding duty without mandating the sort of granular, Member State-specific source apportionment the applicants say would be necessary to satisfy polluter-pays, proportionality, and equal treatment.

(d) The Court’s restraint on a “proposed answer”

A striking passage is the Court’s statement that, because the State did not meaningfully address the validity critique on evidence or law (beyond general denial and pointing to the EU legislature), the Court was “not in a position” to offer a meaningful provisional view. This underscores an institutional point: a national court can (and often must) refer validity questions where the dispute is real, even if the national record is incomplete and the key defence is expected to be advanced by the EU institutions and participating Member States before the CJEU.

3.3 Impact

(a) Procedural impact in Irish/EU litigation

  • Earlier access to Luxembourg: The judgment reinforces that anticipated implementation can suffice for a validity reference, reducing the need to wait for transposition where the contested burden is embedded in the Directive itself.
  • Record-building: It signals that applicants can use affidavit evidence and expert reports to show an arguable validity issue at reference stage—particularly for “manifest error” challenges—without forcing the national court to resolve the scientific dispute.
  • State posture matters: Where the State takes the position that the EU institutions should defend validity and provides little substantive rebuttal, the national court may still refer but may decline to provide a proposed answer.

(b) Substantive policy impact (pending CJEU outcome)

Although the High Court did not decide merits, the question it frames highlights fault-lines likely to recur in EU environmental regulation:

  • Sectoral cost allocation under polluter pays: whether imposing an 80% minimum on only medicines/cosmetics is compatible with Article 191(2) TFEU where other micropollutant sources are not included in Annex III.
  • Health-system sensitivity (Article 168 TFEU): whether the EU legislature must more explicitly account for affordability/availability of medicines when designing EPR funding rules.
  • Feasibility and timing: whether the compliance timetable (including the 31 December 2028 operational horizon referenced in the question) is proportionate given alleged regulatory lead times for reformulation/substitution in pharmaceuticals.

If the CJEU were ultimately to find invalidity (in whole or part), Member States’ transposition strategies and funding models for quaternary treatment could require redesign. Conversely, if upheld, the Directive would stand as a strong endorsement of EU-wide EPR mechanisms even where cost burdens are concentrated on particular product categories defined at EU level.

4) Complex Concepts Simplified

  • Preliminary reference (Article 267 TFEU): a mechanism allowing (and sometimes requiring) national courts to ask the CJEU to rule on EU-law interpretation or on the validity of EU acts. The national case is paused while the CJEU answers.
  • Extended Producer Responsibility (EPR): rules making producers financially responsible for downstream environmental costs associated with their products. Here, it is used to fund advanced wastewater treatment aimed at removing micropollutants.
  • Polluter pays principle (Article 191(2) TFEU): an EU environmental principle that those responsible for pollution should bear the costs of managing it, rather than shifting costs to the public generally.
  • Quaternary treatment: an advanced stage of wastewater treatment (beyond primary/secondary/tertiary) designed to remove micropollutants such as residues of pharmaceuticals and personal care products.
  • Manifest error: a public-law standard of review used where a legislature or decision-maker has made a clearly wrong assessment, particularly in complex scientific, technical, or economic fields. The applicants’ evidence is aimed at showing the EU legislature relied on flawed assumptions/data.
  • Proportionality / equal treatment / legal certainty: general EU law principles requiring (respectively) that measures not go beyond what is necessary, that comparable situations not be treated differently without objective justification, and that legal rules be clear and predictable.

5) Conclusion

Irish Pharmaceutical Healthcare Association [2026] IEHC 310 is primarily a procedural milestone: it confirms that Irish judicial review can provide a sufficiently “genuine dispute” to justify a validity reference to the CJEU even before implementing measures are made, particularly where transposition is imminent and the contested obligations arise from the EU instrument itself. The decision also illustrates a pragmatic approach to contested scientific/economic evidence at referral stage—using it to demonstrate an arguable issue while reserving merits for Luxembourg.

The ultimate significance will depend on the CJEU’s response to the carefully framed validity question, which squarely tests the compatibility of the Directive’s 80% EPR cost allocation (focused on medicines and cosmetics) with Article 168 TFEU, polluter pays, and core EU-law principles.